Tamra Sami

Perth

Staff Writer at BioWorld

Staff Writer at Clarivate

Science writer, editor, publication manager with product development, Asia and emerging markets expertise.

Featured in: Favicon

bioworld.com Favicon

usnews.com Favicon

endpts.com Favicon

biopharmadive.com Favicon

centerwatch.com Favicon

biocentury.com Favicon

pharmamedtechbi.com

Articles

Ascletis’ denifanstat meets phase III endpoints in acne

2 days ago | bioworld.com | Tamra Sami

Ascletis’ denifanstat meets phase III endpoints in acne Ascletis Pharma Inc.’s once-daily oral fatty acid synthase inhibitor, denifanstat, demonstrated statistically significant and clinically meaningful improvements compared to placebo, meeting all primary and secondary endpoints in a phase III trial for moderate to severe acne vulgaris. BioWorld Clinical Dermatologic Small molecule Asia-Pacific China U.S.
ASCO 2025: Dizal's new chemical entities for lung, blood cancers

3 days ago | bioworld.com | Tamra Sami

ASCO 2025: Dizal's new chemical entities for lung, blood cancersDizal (Jiangsu) Pharmaceutical Co. Ltd.’s LYN/BTK dual inhibitor, DZD-8586, saw tumor shrinkage in 94.1% of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma following Bruton's tyrosine kinase inhibitors, the company reported during an oral presentation at the American Society of Clinical Oncology (ASCO) 2025 conference.
Anatara takes a second look at Garp after phase II IBS miss

4 days ago | bioworld.com | Tamra Sami

Anatara takes a second look at Garp after phase II IBS missAfter reporting in April that its gastrointestinal reprogramming product (Garp) failed to meet the primary efficacy endpoint in a phase II trial in irritable bowel syndrome (IBS), Anatara Lifesciences Ltd. conducted a further analysis that shows a positive trend toward efficacy. BioWorld Asia Clinical Gastrointestinal Inflammatory Small molecule
Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B

1 week ago | bioworld.com | Tamra Sami

Home » Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34BAstellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34BIn yet another China antibody-drug conjugate (ADC) deal, Astellas Pharma Inc. is inlicensing a phase I/II ADC targeting Claudin 18.2 from Evopoint Biosciences Co. Ltd. for up to $1.34 billion. BioWorld Deals and M&A Cancer Antibody-drug conjugate Asia-Pacific China Japan
Singapore’s Quadria Capital closes $1B health care-focused fund

1 week ago | bioworld.com | Tamra Sami

Singapore’s Quadria Capital closes $1B health care-focused fundAsian health care-focused private equity firm Quadria Capital announced the final close of its Fund III with $1.07 billion in total commitments to transform health care across Asia, which is expected to drive 40% of global health care growth by 2030. BioWorld MedTech Financings Asia-Pacific
Singapore’s Quadria Capital closes $1B health care-focused fund

1 week ago | bioworld.com | Tamra Sami

Singapore’s Quadria Capital closes $1B health care-focused fundAsian health care-focused private equity firm Quadria Capital announced the final close of its Fund III with $1.07 billion in total commitments to transform health care across Asia, which is expected to drive 40% of global health care growth by 2030. BioWorld Financings Asia-Pacific
EBR Systems raises $36M to sell Wise CRT therapy

1 week ago | bioworld.com | Tamra Sami

City hits the town with $1B-plus deal with BiogenA development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
Anatara takes a second look at Garp after phase II IBS miss

1 week ago | bioworld.com | Tamra Sami

Anatara takes a second look at Garp after phase II IBS missAfter reporting in April that its gastrointestinal reprogramming product (Garp) failed to meet the primary efficacy endpoint in a phase II trial in irritable bowel syndrome (IBS), Anatara Lifesciences Ltd. conducted a further analysis that shows a positive trend toward efficacy. BioWorld Clinical Gastrointestinal Inflammatory Small molecule
Annji's phase I/II positive in spinal, bulbar muscular atrophy

1 week ago | bioworld.com | Tamra Sami

Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
Adalta sees promise in new 'East to West' strategy for T-cell therapies

1 week ago | bioworld.com | Tamra Sami

Adalta sees promise in new 'East to West' strategy for T-cell therapies Adalta Ltd. is outlicensing all of its internal products and focusing instead on inlicensing early stage T-cell assets from Asia, mostly from China, Adalta CEO Tim Oldham told BioWorld.